

1 **Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2** 2 **infection**

3 Marchi S^{1#}, Viviani S^{#1}, Remarque EJ², Ruello A³, Bombardieri E^{3°}, Bollati V⁴, Milani GP^{4,5},
4 Manenti A^{6,7}, Lapini G⁷, Rebuffat A⁸, Montomoli E^{1,6,7} and Trombetta CM^{1*}

5 ¹Department of Molecular and Developmental Medicine, University of Siena, Via Aldo Moro, 2, 53100, Siena, Italy.

6 ²Department of Virology, Biomedical Primate Research Centre, Lange Kleiweg, 161, 2288 GJ Rijswijk, The Netherlands.

7 ³Medical Analysis Laboratory, Humanitas Gavazzeni, Via Mauro Gavazzeni, 21, 24125, Bergamo, Italy.

8 ^{3°}Scientific Director, Humanitas Gavazzeni, Via Mauro Gavazzeni, 21, 24125, Bergamo, Italy.

9 ⁴EPIGET Lab, Department of Clinical Sciences and Community Health, University of Milan, Via San Barnaba, 8, 20122,
10 Milan, Italy.

11 ⁵Pediatric Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via della Commedia, 10, 20122, Milan,
12 Italy.

13 ⁶VisMederi srl, Strada del Petriccio e Belriguardo, 35, 53100, Siena, Italy.

14 ⁷VisMederi Research srl, Strada del Petriccio e Belriguardo, 35, 53100, Siena, Italy.

15 ⁸Presidio Ospedaliero di Campostaggia, Località Campostaggia, 53036, Poggibonsi, Italy.

16

17 [#]These authors contributed equally to this article.

18 *trombetta@unisi.it

19 **ABSTRACT**

20 SARS-CoV-2 pandemic is causing high morbidity and mortality burden worldwide with
21 unprecedented strain on health care systems.

22 To elucidate the mechanism of infection, protection, or rapid evolution until fatal outcome of the
23 disease we performed a study in hospitalized COVID-19 patients to investigate the time course of the
24 antibody response in relation to the outcome. In comparison we investigated the time course of the
25 antibody response in SARS-CoV-2 asymptomatic subjects.

26 Study results show that patients produce a strong antibody response to SARS-CoV-2 with high
27 correlation between different viral antigens (spike protein and nucleoprotein) and among antibody
28 classes (IgA, IgG, and IgM and neutralizing antibodies). The peak is reached by 3 weeks from hospital
29 admission followed by a sharp decrease. No difference was observed in any parameter of the antibody
30 classes, including neutralizing antibodies, between subjects who recovered or with fatal outcome.
31 Only few asymptomatic subjects developed antibodies at detectable levels.

32 **KEYWORDS**

33 SARS-CoV-2 pandemic, COVID-19 patients, SARS-CoV-2 asymptomatic subjects, antibody
34 response.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35 INTRODUCTION

36 On March 11, 2020, the World Health Organization (WHO) Director General declared a pandemic
37 situation due to a novel coronavirus causing a Severe Acute Respiratory Syndrome (SARS) rapidly
38 spreading worldwide [1]. The novel coronavirus (CoV) SARS-CoV-2 has been firstly identified in
39 Wuhan, the capital city of Hubei Province, China, at the end of 2019 when a cluster of atypical
40 pneumonia was identified [1, 2]. In January 2020, SARS-CoV-2 was isolated and sequenced as a
41 CoV genetically related to the highly pathogenic CoV (SARS-CoV-1) responsible for the 2003 SARS
42 outbreak. CoV s are known to cause disease in humans. There are four CoVs responsible for the
43 common cold and another one highly pathogenic known as Middle Eastern Respiratory Syndrome
44 (MERS)-CoV [2-6]. SARS-CoV-1 caused a global pandemic with approximately 10% case fatality
45 rate (CFR) [7]. However, SARS-CoV-1 has stopped circulating in humans since 2004. MERS-CoV
46 was first reported from Saudi Arabia in 2012 and has continued to infect humans in 27 countries with
47 limited human-to-human transmission, and a CFR of approximately 34.4%, according to the most
48 recent WHO report [7]. As SARS-CoV-1 and MERS-CoV, the SARS-CoV-2 virus is an enveloped,
49 single-stranded, and positive-sense RNA virus belonging to the Betacoronavirus Genus,
50 *Coronaviridae* family. The genome of SARS-CoV-2, as the other emerging pathogenic human CoVs,
51 encodes four major structural proteins: spike (S), envelope (E), membrane (M), nucleocapsid (N);
52 approximately 16 nonstructural proteins (nsp1–16), and five to eight accessory proteins. Among
53 them, the S protein plays an essential role in viral attachment, fusion, entry, and transmission. The S
54 protein is the common target antigen for neutralizing antibodies and vaccine development [8-11].
55 SARS-CoV-2 predominant transmission way was identified early to be a human-to-human mode
56 occurring through respiratory droplets, however, close contact with infected surfaces or objects may
57 also be an occasional way of transmission. The virus is excreted and detectable in saliva and stool [5,
58 9, 12]. SARS-CoV-2 disease, or COVID-19, ranges from a mild upper/lower respiratory tract
59 infection that resolves in a few days without sequelae to more serious disease with fever, cough,
60 shortness of breath, myalgias, fatigue, confusion, headache, sore throat, acute respiratory distress
61 syndrome, leading to respiratory or multiorgan failure [5, 9, 12]. The fatality rate is high in people

62 with underlying comorbidities, particularly in the elderly, such as diabetes, hypertension, chronic
63 respiratory disease or cardiovascular disease [9, 12]. After almost one year after the first cases were
64 reported in Wuhan, as of 13 December 2020, there have been over 70 million cases and over 1.5
65 million deaths reported to WHO of confirmed COVID-19 [13] with Europe being one of the most
66 affected areas, second only to the Americas. COVID-19 pandemic is causing high morbidity and
67 mortality burden worldwide, an unprecedented strain on health care systems, with social and
68 economic disruption as the only effective prevention is social distancing leading entire countries in
69 quarantine for weeks or months with dramatic impact on day-to-day human, social and economic life
70 [14].

71 Italy has been one of the earliest and most affected countries by COVID-19. Although the first SARS-
72 CoV-2 case identified in Codogno at the end of February 2020 is considered the Italian index case,
73 some evidence has later arisen that the virus had circulated in Italy and Europe since autumn 2019
74 [15-18]. Italy suffered the first wave from February until June 2020 when the whole country was
75 under strict lockdown. During this period the most affected areas were located in Northern and to a
76 less extent in Central Italy, while the Southern part of the country was relatively unaffected [19, 20].
77 During the summer period until the end of September 2020 COVID-19 remained endemic, with a
78 second epidemic wave starting in October 2020 that led to a second national lockdown in November
79 2020. As of the 13th of December 2020, more than 1.8 million confirmed cases and more than 64.000
80 deaths due to SARS-CoV-2 were reported to ISS (Istituto Superiore di Sanità), Rome [21]. The mean
81 age of fatalities in COVID-19 infected people was 80 years, 42,4% were women and more than 90%
82 had one or more co-morbidity as ischemic heart disease, diabetes, active cancer, atrial fibrillation,
83 dementia, and a history of stroke [19].

84 The emerging and rapid diffusion of COVID-19 has risen the calls for more targeted research in the
85 field [22] helping to elucidate the mechanism of infection, protection, or rapid evolution until fatal
86 outcome of the disease. We present here a study performed in hospitalized infected COVID-19
87 patients to investigate the time course of the antibody response in relation to the outcome, and as

88 explorative comparison, we also investigated the time course of the antibody response in SARS-CoV-
89 2 asymptomatic subjects.

90 **MATERIAL AND METHODS**

91 **Study population**

92 This was a retrospective study on COVID-19 patients and SARS-CoV-2 asymptomatic subjects
93 during the first epidemic wave occurred in Italy between March and May 2020.

94 A total of 42 COVID-19 patients, hospitalized at Humanitas Gavazzeni (Bergamo, Italy), were
95 retrospectively selected for this study, of whom 35 (22 males and 13 females) recovered and 7 (3
96 males and 4 females) had a fatal outcome. All subjects were admitted to hospital with a diagnosis of
97 interstitial pneumonia confirmed by chest radiograph or a CAT (computerized axial tomography) and
98 had rhino-pharyngeal swab positive to SARS-CoV-2 (Real-Time PCR Thermo Fisher Scientific). Six
99 patients required care in the intensive care unit (ICU), the others were hospitalized in the general
100 medicine unit. Out of 7 deceased patients, 3 were hospitalized in ICU and 4 in the general medicine
101 unit.

102 Serum samples were collected at different time points from March to April 2020 for
103 diagnostic/therapeutic purposes. We selected patients who had available at least 5 blood samples
104 during the period of hospital admission (baseline, day 2, day 6, day 12-14, day 18-20, day 27-30).
105 Demographic and clinical variables reported in this study were those collected at hospital admission.
106 For the purpose of this study patients were categorized according to the outcome: recovered or
107 deceased.

108 During the first phase of the COVID-19 epidemic, little was known about this novel CoV and there
109 was no standard therapy, so the management changed over the time. The Italian Society of Infectious
110 and Tropical Diseases recommended as therapy hydroxychloroquine, antiviral agents, steroids, low
111 molecular weight heparin and oxygen support in different combinations according to the clinician's
112 evaluation. The antibiotic therapy was adopted only in case of suspected or confirmed bacterial
113 superinfection.

114 Serum samples from 25 asymptomatic subjects who presented a positive nasal swab for SARS-CoV-
115 2 were collected as part of the UNICORN project and were analysed in the present study [23].

116 This study was approved by the Ethics Committee of the University of Siena (approval number
117 17373, approval date June 1, 2020), by the Ethics Committee of Humanitas Gavazzeni (approval
118 number 236, approval date September 22, 2020 Protocol 670/20). The UNICORN study was
119 approved by the Ethics Committee of the University of Milan (approval number 17/20, approval date
120 March 6, 2020).

121 **Serological assay**

122 **ELISA**

123 All serum samples were tested by commercial ELISA for the detection of IgA, IgG, and IgM against
124 the S1 of SARS-CoV-2 (Aeskulisa[®] SARS-CoV-2 S1 IgA, IgM, IgG, Aesku.Diagnostics,
125 Wendelsheim, Germany) and for the detection of IgG against the nucleoprotein (NP) of SARS-CoV-
126 2 (Aeskulisa[®] SARS-CoV-2 NP IgG, Aesku.Diagnostics, Wendelsheim, Germany).

127 According to the manufacturer's instructions, quantitative analysis was performed by use of a 4-
128 parameter logistic standard curve obtained by plotting the optical density (OD) values measured for
129 4 calibrators against their antibody activity (U/ml) using logarithmic/linear coordinates. Antibody
130 activities of the samples were evaluated from OD values using the generated curve and considered
131 positive if >12 U/ml.

132 **Virus Neutralization assay**

133 The virus neutralization (VN) assay has been performed as previously reported [24]. Briefly, serum
134 samples were heat-inactivated for 30 minutes at 56°C and, starting from 1:10 dilution, were mixed
135 with an equal volume of SARS-CoV-2 (2019-nCov/Italy-INMI1 strain) viral solution containing 100
136 Tissue Culture Infective Dose 50% (TCID₅₀). After 1 hour of incubation at room temperature, 100µl
137 of virus-serum mixture were added to a 96-well plate containing an 80% confluent Vero E6 cell
138 monolayer. Plates were incubated for 3 days at 37°C, 5% CO₂ in humidified atmosphere, then
139 inspected for presence/absence of cytopathic effect (CPE) by means of an inverted optical

140 microscope. A CPE higher than 50% indicated infection. The VN titer was expressed as the reciprocal
141 of the highest serum dilution showing protection from viral infection and CPE.

142 **Statistical analysis**

143 All statistical analyses were performed using Microsoft R-Open version 3.5.0 (R Core Team (2018)).
144 R: A language and environment for statistical computing. R Foundation for Statistical Computing,
145 Vienna, Austria. URL <https://www.R-project.org/>). For patient baseline characteristics continuous
146 variables were evaluated using Mann-Whitney tests and for categorical variables Chi-square tests
147 were used. Seroconversion rates were compared using Fisher's exact test. Antibody levels were
148 statistically evaluated using t-tests. Statistical significance was set at $p < 0.05$, two tailed.

149 **RESULTS**

150 **COVID-19 patients**

151 Between March and April 2020, a total of 42 subjects were retrospectively selected for this study, of
152 whom 35 recovered and 7 had a fatal outcome. The median age at admission was 64.0 years
153 (interquartile range (IQR) 56.0-71.5) for those who recovered and 69.0 years (IQR 64.5-72.0) for
154 deceased patients. The median length of stay in the hospital was similar in both groups with 11.0 days
155 (IQR 9.0-24.5) and 10.0 (IQR 6.0-15.59) for recovered and deceased patients, respectively. The mean
156 number of pre-existing conditions in recovered and deceased was 1.53 (standard deviation (SD) 1.25)
157 and 2.0 (SD 1.41), respectively, and comorbidities were indicated in 1.88 (SD 1.36) and 3.5 (SD 3.54)
158 of recovered and deceased patients, respectively. No differences were found between recovered and
159 deceased patients when compared for symptoms at admission (fever, cough, diarrhea, dyspnea) or
160 presence/absence of comorbidities and/or preexisting conditions. The other demographic, clinical,
161 and blood chemistry variables collected at baseline were similar between the two groups, with
162 exception of ALT that showed to be statistically significantly higher (p-value 0.021) in subjects who
163 recovered (Table 1a).

164 At hospital admission, 15 subjects (35.7%) were negative for S1 IgM, 11 (26.2%) for S1 IgA, 13
165 (30.9%) for S1 IgG, 15 (35.7%) for NP IgG, and 10 (23.8%) for neutralizing antibodies. Five subjects
166 (11.9%) were negative to any antibody assay at the time of admission; of these, 2 died and 3

167 recovered. Two days after admission, 6 subjects (14.3%) were still negative for S1 IgM, 7 (16.7%)
168 for S1 IgA, 4 (9.5%) for S1 IgG, 3 (7.1%) for NP IgG, and 5 (11.9%) for neutralizing antibodies.
169 Two subjects (4.8%) were still negative to any antibody assay; of these, 1 died and 1 recovered. At 6
170 days of sample collection, all subjects except one (97.6%) were positive to all assays (Figures 1-5).
171 The exception was represented by a 40-year-old male subject, showing neither S1 IgM nor S1 IgA
172 positivity in any sample, NP IgG with a borderline result at admission and at day 2, and negative at
173 day 6, and neutralizing antibody titers less or equal than 40. This subject presented fever and dyspnea
174 at admission with no comorbidities or preexisting conditions and recovered in 12 days.

175 Two subjects, one recovered and one deceased both within 6 days after admission, were both negative
176 to NP IgG at admission and at day 2. Two subjects, both recovered, were positive only for neutralizing
177 antibodies at admission, with titers less or equal to 40. Both showed positivity to all antibodies tested
178 at day 2 and later (Figures 1-5).

179 Neutralizing antibodies were found in all patients, with a range from 10 to 5120.

180 Antibody titers for patients are presented in table 2. S1 and NP antibodies started increasing at day 2
181 and again at day 6. A decrease for all antibodies was observed in recovered patients at day 27-30. S1
182 antibody increase was similar in both recovered and deceased patients, while NP IgG titers were
183 significantly higher in deceased patients at day 6 (p-value 0.044). At baseline neutralizing antibody
184 titers in recovered patients were 40.8 (95%CI 1.3 -1296.4) and 24.4 (95%CI 0.2- 3093.8) in those
185 deceased. Already at day 6, neutralizing antibody titers had increased steadily with 427.9 (95% CI
186 29.0 - 6321.5) in recovered patients and 226.3 (95% CI 12.1 -4228.2) in those deceased and showed
187 a plateau in recovered patients until day 18-20. At day 27-30, neutralizing antibody titers had declined
188 in recovered. No significant difference between the two groups, however comparison for the last days
189 collection was not possible for few subjects in the deceased group.

190 Considering seroconversion rates in comparison to baseline (Table 3), IgM seroconversion rate
191 appeared higher in the deceased (p-value 0.043).

192 No statistically significant difference in antibody titers at baseline and by peak antibody level (all 5
193 assays combined) was found between those survivors and deceased by using the Cox proportional

194 hazard model. A good correlation was found among all assays (Figure 6). Overall, the level of S1
195 specific response was well correlated among antibody types ($r=0.781$ and $r=0.794$, S1 IgG correlating
196 with S1 IgA and S1 IgM, respectively; $r=0.760$ S1 IgA correlating with S1 IgM). S1 IgG response
197 was highly correlated with NP IgG ($r=0.834$). Neutralizing antibodies well correlated with all ELISA
198 antibodies tested ($r=0.722$ with S1 IgA, $r=0.798$ with S1 IgM, $r=0.739$ with S1 IgG, and $r=0.730$ with
199 NP IgG).

200 **Table 1a. Baseline characteristics of COVID-19 patients according to outcome. Median (IQR)**

<i>Parameter</i>	<i>Recovered</i>	<i>Deceased</i>	<i>P-value</i>
Sex	22 M / 13 F	3 M / 4 F	0.574
Age	64.0 (56.0 to 71.5)	69.0 (64.5 to 72.0)	0.279
Length of stay	11.0 (9.0 to 24.5)	10.0 (6.0 to 15.5)	0.498
ICU	3 yes / 32 no	3 yes / 4 no	0.076
WBC	7.1 (5.8 to 9.7)	8.8 (5.5 to 11.6)	0.800
RBC	4.2 (3.9 to 4.6)	4.6 (4.1 to 4.9)	0.273
Hb	13.2 (12.2 to 14.3)	13.9 (13.2 to 14.0)	0.649
PLT	202.0 (152.5 to 298.0)	165.0 (134.0 to 283.0)	0.673
Neutrophils	6.2 (4.2 to 8.1)	6.9 (4.5 to 10.2)	0.673
Lymphocytes	0.9 (0.7 to 1.3)	0.4 (0.4 to 0.7)	0.075
AST	52.0 (31.5 to 80.0)	46.0 (35.0 to 52.0)	0.418
ALT	40.0 (25.5 to 64.5)	23.0 (22.5 to 29.0)	0.021
LDH	382.0 (279.0 to 527.5)	602.0 (400.5 to 680.5)	0.147
GGT	46.0 (34.0 to 96.5)	60.0 (23.0 to 73.0)	0.566
Creatinine	0.9 (0.8 to 1.0)	1.0 (0.9 to 1.1)	0.380
CRP	12.6 (7.9 to 16.1)	10.6 (7.9 to 13.5)	0.716
Ferritin	544.0 (315.5 to 1310.0)	1079.0 (967.5 to 1301.0)	0.224
Fibrinogen	591.0 (446.0 to 650.5)	577.0 (447.0 to 602.0)	0.500
D-Dimer	1383.0 (669.0 to 2261.5)	1137.0 (962.5 to 1733.5)	1.000
Fever*	33 yes / 2 no	7 yes / 0 no	1.000
Cough*	7 yes / 28 no	3 yes / 4 no	0.418
Diarrhea*	5 yes / 30 no	1 yes / 6 no	1.000
Dyspnea*	26 yes / 9 no	6 yes / 1 no	0.871
Comorbidities	17 yes / 18 no	2 yes / 5 no	0.579
Preexisting conditions	15 yes / 20 no	2 yes / 5 no	0.779

201
202 ICU, Intensive care unit; WBC, white blood cells (103/mm³); RBC, red blood cells (10⁶/mm³); Hb, haemoglobin (gr/dl);
203 PLT, platelets (10³/mm³); AST, Aspartate aminotransferase (UI/l); ALT, Alanine aminotransferase (UI/l); LDH, lactate
204 dehydrogenase (U/l); GGT, Gamma Glutamyl Transferase (UI/l); CRP, C reactive protein (mg/l).

205
206 Neutrophils (103/mm³); Lymphocytes (103/mm³); Creatinine (mg/dl); Ferritin (ug/l); Fibrinogen (g/l); D-Dimer
207 (mcg/ml).

208 *Fever: a measured temperature of 100.4° F (38° C) or greater, or with a history of feeling feverish.; Cough: continuous
209 cough for more than an hour, or 3 or more coughing episodes in 24 hours; Diarrhea: loose, watery stools that occur more
210 frequently than usual (at least 3 episodes within a 24-hour period); Dyspnea: difficult or labored breathing; shortness of
211 breath.

212

213 **Asymptomatic SARS-CoV-2 infected subjects**

214 Asymptomatic infected subjects serum was made available as part of the UNICORN project [23].
215 The median age of asymptomatic subjects was 45.0 years (IQR 36.0-60.0), 8 were males and 17
216 females (Table 1b). Twenty-one subjects had the swab positive to SARS-CoV-2 in March 2020 and
217 a blood draw, of whom 19 subjects had a blood draw in May and 14 another blood draw in September.
218 Four subjects had the swab positive to SARS-CoV-2 in May and a blood draw, of whom 1 had a
219 second blood draw in September.

220 Out of 25 asymptomatic subjects, 16 (64.0%) were negative to any antibody at any time point. Nine
221 subjects (36.0%) had at least one detectable antibody type at least at one of the time points. At the
222 first time point 6 subjects (24.0%) had positive S1 IgG, of whom 2 also had S1 IgA and NP IgG, 1
223 also S1 IgM, S1 IgA and NP IgG and 1 had S1 IgA, NP IgG and positive neutralizing antibodies.
224 Three subjects negative at any antibody at the first time points had antibodies at one of the subsequent
225 time points. One of these subjects was positive at any antibody assay at the second time point
226 including neutralizing antibodies. The other 2 subjects had S1 IgA, S1 IgG and NP IgG at the third
227 time point. One subject was positive to all ELISA antibodies (S1 IgM, S1 IgA, S1 IgG, and NP IgG)
228 at the first time point, negative at the second time point, and positive again only to S1 IgG at the third
229 time point. Detectable neutralizing antibodies were found only in 2 subjects (8.0%), one at the first
230 and only time point available and in the other one at the second time point, the third time point wasn't
231 available. Both subjects were also positive to S1 IgA, S1 IgG, and NP IgG; only the first one was also
232 positive to S1 IgM.

233 Asymptomatic subjects with positive antibody levels in any of the assays had titers well below the
234 level found in symptomatic subjects as shown in figures 1-5 (table 4).

235

236

237

238

239

240
241

Table 2. Comparison of immune responses in recovered versus deceased COVID-19 patients. ELISA titres are expressed as U/ml

<i>Antibody</i>	<i>Day</i>	<i>N</i>	Recovered		Deceased		<i>Ratio D/R</i>	<i>P-value</i>
			<i>GMT (95% CI)</i>	<i>N</i>	<i>GMT (95% CI)</i>			
S1 IgM	Baseline	35	19.6 (0.5 to 718.5)	7	5.0 (0.0 to 12159.3)	0.25 (0.01 to 4.89)	0.308	
	Day 2	35	46.9 (3.0 to 732.2)	7	17.4 (0.0 to 9381.0)	0.37 (0.03 to 4.03)	0.356	
	Day 6	31	126.7 (16.9 to 951.6)	6	146.4 (34.5 to 621.4)	1.16 (0.61 to 2.17)	0.627	
	Day 12-14	18	111.5 (9.7 to 1284.4)	3	177.7 (29.9 to 1057.1)	1.59 (0.70 to 3.63)	0.232	
	Day 18-20	12	107.3 (15.6 to 737.9)	2	119.4 (1.7 to 8251.2)	1.00 (1.00 to 1.00)		
	Day 27-30	8	64.4 (5.3 to 788.3)	1	79.2 (0.0 to 0.0)	1.00 (1.00 to 1.00)		
S1 IgA	Baseline	35	17.8 (0.6 to 497.5)	7	6.8 (0.0 to 21390.7)	0.38 (0.02 to 8.03)	0.473	
	Day 2	35	42.9 (3.2 to 571.6)	7	34.6 (0.5 to 2510.1)	0.81 (0.16 to 4.13)	0.768	
	Day 6	31	96.4 (14.1 to 659.6)	6	118.3 (16.4 to 854.9)	1.23 (0.54 to 2.78)	0.581	
	Day 12-14	18	100.2 (15.5 to 646.2)	3	187.0 (10.0 to 3493.1)	1.87 (0.48 to 7.23)	0.249	
	Day 18-20	12	108.0 (38.2 to 305.2)	2	95.8 (0.0 to 10573636.2)	1.00 (1.00 to 1.00)		
	Day 27-30	8	79.7 (13.6 to 465.8)	1	206.7 (0.0 to 0.0)	1.00 (1.00 to 1.00)		
S1 IgG	Baseline	35	16.8 (0.1 to 1966.3)	7	6.2 (0.0 to 21044.6)	0.37 (0.02 to 8.18)	0.476	
	Day 2	35	66.3 (2.2 to 1956.6)	7	33.5 (0.0 to 147927.2)	0.50 (0.02 to 12.13)	0.623	
	Day 6	31	355.8 (90.2 to 1403.1)	6	403.3 (212.0 to 767.1)	1.13 (0.82 to 1.57)	0.436	
	Day 12-14	18	397.6 (115.7 to 1366.9)	3	392.4 (65.8 to 2339.2)	0.99 (0.44 to 2.22)	0.964	
	Day 18-20	12	408.9 (160.9 to 1038.9)	2	344.5 (0.4 to 335188.3)	1.00 (1.00 to 1.00)		
	Day 27-30	8	202.7 (151.6 to 271.0)	1	220.8 (0.0 to 0.0)	1.00 (1.00 to 1.00)		
NP IgG	Baseline	35	18.1 (0.5 to 647.9)	7	10.8 (0.0 to 2898.3)	0.60 (0.07 to 5.03)	0.588	
	Day 2	35	70.3 (2.0 to 2416.5)	7	71.7 (0.1 to 68291.3)	1.02 (0.08 to 13.77)	0.987	
	Day 6	31	411.9 (32.3 to 5248.2)	6	756.0 (246.1 to 2323.1)	1.84 (1.02 to 3.32)	0.044	
	Day 12-14	18	466.7 (30.1 to 7248.5)	3	725.4 (24.0 to 21884.1)	1.55 (0.34 to 7.06)	0.467	
	Day 18-20	12	371.8 (59.2 to 2333.6)	2	550.5 (0.0 to 6914416.1)	1.00 (1.00 to 1.00)		
	Day 27-30	8	171.3 (43.6 to 672.3)	1	262.0 (0.0 to 0.0)	1.00 (1.00 to 1.00)		
NAb	Baseline	35	40.8 (1.3 to 1296.4)	7	24.4 (0.2 to 3093.8)	0.60 (0.09 to 3.81)	0.539	
	Day 2	35	75.4 (3.2 to 1754.7)	7	32.8 (0.6 to 1907.7)	0.44 (0.09 to 2.07)	0.255	
	Day 6	31	427.9 (29.0 to 6321.5)	6	226.3 (12.1 to 4228.2)	0.53 (0.16 to 1.77)	0.257	
	Day 12-14	18	373.3 (27.5 to 5071.8)	3	285.1 (6.7 to 12155.4)	0.76 (0.14 to 4.21)	0.670	
	Day 18-20	12	508.0 (79.9 to 3229.0)	2	113.1 (0.0 to 14707762061.6)	1.00 (1.00 to 1.00)		
	Day 27-30	8	190.3 (16.0 to 2267.5)	1	160.0 (0.0 to 0.0)	1.00 (1.00 to 1.00)		

242 NAb, neutralizing antibody.

243

244

245

246

247

248

249

250
251

Table 3. Seroconversion in COVID-19 patients according to outcome. Seroconversion (SC) was calculated as 4-fold increase in titre compared to baseline

<i>Antibody</i>	<i>Day</i>	<i>Recovered</i>		<i>Deceased</i>		<i>P-value</i>
		<i>SC Yes</i>	<i>SC No</i>	<i>SC Yes</i>	<i>SC No</i>	
S1 IgM	Day 2	6	29	4	3	0.043
	Day 6	19	12	4	2	1.000
	Day 12-14	11	7	2	1	1.000
	Day 18-20	7	5	1	1	1.000
	Day 27-30	4	4	1	0	1.000
S1 IgA	Day 2	8	27	3	4	0.353
	Day 6	20	11	4	2	1.000
	Day 12-14	12	6	2	1	1.000
	Day 18-20	8	4	1	1	1.000
	Day 27-30	5	3	1	0	1.000
S1 IgG	Day 2	11	24	5	2	0.085
	Day 6	23	8	4	2	0.653
	Day 12-14	13	5	2	1	1.000
	Day 18-20	9	3	1	1	0.505
	Day 27-30	4	4	1	0	1.000
NP IgG	Day 2	16	19	6	1	0.096
	Day 6	24	7	5	1	1.000
	Day 12-14	14	4	2	1	1.000
	Day 18-20	9	3	1	1	0.505
	Day 27-30	7	1	1	0	1.000
NAb	Day 2	5	30	1	6	1.000
	Day 6	22	9	4	2	1.000
	Day 12-14	13	5	2	1	1.000
	Day 18-20	9	3	1	1	0.505
	Day 27-30	6	2	1	0	1.000

252 NAb, neutralizing antibody.

253

254 **Table 1b. Baseline characteristics of SARS-CoV-2 asymptomatic subjects. Median (IQR)**

<i>Parameter</i>	<i>Statistics</i>
Sex	8 M / 17 F
Smoke	14 never, 5 stopped, 5 active
Age	45.0 (36.0 to 60.0)
BMI	22.8 (21.5 to 24.6)

255 BMI, Body Mass Index.

256 **Table 4. Comparison of baseline immune responses for Recovered or Deceased versus asymptomatic controls**

<i>Antibody</i>	<i>Recovered/ Asymptomatic</i>	<i>P value</i>	<i>Deceased / Asymptomatic</i>	<i>P value</i>
S1 IgM	286 (111 to 734)	1.42E-15	73 (4 to 1448)	0.0111
S1 IgA	172 (71 to 422)	6.05E-15	65 (3 to 1351)	0.0145
S1 IgG	96 (27 to 338)	4.86e- 9	36 (2 to 798)	0.0295
NP IgG	7.3 (3.7 to 14.3)	3.22e- 7	4.3 (0.5 to 36.3)	0.142
NAb	8.2 (4.6 to 14.6)	1.88e- 8	4.9 (0.8 to 30.5)	0.0785

257

258 **DISCUSSION**

259 In this study we primarily evaluated the time course of the antibody response to different antigens of
260 SARS-CoV-2 (IgG, IgM, and IgA against S1, IgG against NP, and neutralizing antibodies) in
261 COVID-19 patients admitted to hospital for pneumonia during the first epidemic wave in March and
262 April 2020 in Italy. No significant difference in titers was observed in any of the S1 antibody class at
263 any time point between patients who survived and who did not survive. However, in deceased
264 patients, a sharper increase of S1 antibodies has been observed suggesting a potential risk factor.
265 Notably, IgM seroconversion rate appeared somewhat higher in the deceased, which might indicate
266 that the deceased were admitted early after infection. In other similar studies early antibody response
267 to S1 IgA or IgM or difference in the magnitude of the immune response to SARS-CoV-2 infection
268 was a predictor of disease severity or progression or outcome [25-28]. IgG antibody titers against NP
269 were significantly higher in the deceased at day 6 according to other studies in which an early
270 response to NP in the first 15 days post-disease onset was indicative of fatal outcomes [25, 27]. Our
271 results did not highlight any difference for neutralizing antibodies in contrast with other studies in
272 which these antibodies were significantly higher in patients who required ICU or died [27]. One
273 explanation for the similar immune response between the two study groups can be that in our study
274 COVID-19 patients had, at admission, similar clinical and demographic characteristics. However,
275 other factors could be implicated in the specific immune response against SARS-CoV-2 that need to
276 be further investigated, as other elements of cellular-mediated immunity may play a role in protection.
277 The kinetics of the antibody response showed an increase starting from day 2 and reaching the peak
278 between days 6 and 18-20. At 27-30 day, a decline in titers was observed for any of the antibody
279 classes. In other studies, the antibody kinetic in COVID-19 patients showed the antibody peak
280 reaching up to the 4th and 5th week from disease onset followed by antibody decay starting at the 6th
281 week [28, 29]. This observation differs from our findings most likely as our study period of patients
282 started at hospital admission when the severity of the disease was already in an advanced stage.
283 In this study, a high correlation between S1 and NP protein-based ELISAs and the neutralization
284 assay was observed in COVID-19 patients. The reason for that is likely due to the fact that the S1

285 protein represents the immunodominant antigen of SARS-CoV-2 virus and functional neutralizing
286 antibodies are mainly targeting the Receptor-Binding Domain, a subunit of that protein [30].
287 In this study, only few asymptomatic subjects had detectable titers with almost two-thirds negative at
288 any time point. These findings support the observation that the use of serology testing for population
289 surveys might account of false negative results as asymptomatic or paucisymptomatic subjects might
290 have antibody concentration below the level of detection [31]. Only few asymptomatic subjects had
291 detectable titers to S1 IgG or more antibodies but with a low level of titers as compared to COVID-
292 19 patients included in this study in accordance with another study [32]. Notably, in contrast to
293 COVID-19 patients, the majority of asymptomatic subjects do not have circulating neutralizing
294 antibodies that are considered a surrogate of protection against COVID-19, thus vaccination is highly
295 recommended. Although further evidence should be provided to establish a correlate of protection,
296 based on these data it can be speculate that evidence of neutralizing antibodies might be used as
297 markers of protective immunity.
298 Asymptomatic subjects have a low viral load in the nasopharynxes as assessed by RT-PCR and most
299 likely a lack or a defective viral replication and/or mucosal invasion that induces a weak or any
300 antibody response [33]. Although memory B and T cells may have been primed in SARS-CoV-2
301 swab positive subjects with undetectable antibodies in serum, with the ability to induce a rapid
302 immune response to re-exposure, the question of whether these subjects should be vaccinated is
303 critical now that effective vaccines are available against COVID-19.
304 One limitation of this study is its retrospective nature and the collection of COVID-19 samples was
305 carried out only in a single center. Besides this, we limited the collection to those patients for whom
306 it was possible to construct an antibody response curve over a period of at least one month. This, of
307 course, represents a bias, however, the ratio between deceased and recovered patients (7 out of 42),
308 16.6% falls in the range from 5.7% to 30.4% as described in the literature [34, 35]. This value shows
309 high variability because it can be influenced both by the characteristics of the series studied and the
310 different treatments. The findings from this study do not allow us to predict the kinetics of the

311 antibody decay over time in patients who recovered from COVID-19, in particular, who will be
312 susceptible to reinfection over time, since no follow-up samples after discharge were available.
313 Overall, our data highlight that COVID-19 patients produce a simultaneous antibody response to
314 SARS-CoV-2 with high correlation between different viral antigens (S1 and NP) and among antibody
315 classes (IgA, IgG, and IgM and neutralizing antibodies). The peak is reached by 3 weeks from hospital
316 admission followed by a sharp decrease. On the contrary, only few asymptomatic subjects developed
317 antibodies at detectable levels, though significantly lower compared to COVID-19 patients. Since
318 neutralizing antibodies were rarely produced, this finding raises the question about the protection of
319 these subjects against reinfection.

320

321 **Author's contributions**

322 S.M.: investigation, data curation, writing – review and editing; S.V.: conceptualization, funding acquisition,
323 writing – original draft preparation; E.J.R.: formal analysis, writing – review & editing; A.R.: resources, data
324 curation, writing – review & editing; E.B.: resources, data curation, writing – review & editing; V.B.:
325 resources, data curation, writing – review & editing; G.P.M: resources, data curation, writing – review &
326 editing; A.M.: methodology, writing – review and editing; G.L.: methodology, writing – review and editing;
327 A.R.; methodology, writing – review and editing; E.M.: methodology, writing – review and editing; C.M.T.:
328 conceptualization, funding acquisition, investigation, project administration, writing – review and editing.

329 **Conflicts of interest statements**

330 The authors declare no conflict of interest.

331 **Acknowledgements**

332 This study was funded by a research grant (Pfizer Tracking Number 60353289).
333 This funding source did not have any role in the design of this study and during its execution, analyses,
334 interpretation of the data, or decision to submit results.
335 This study was supported by the European Virus Archive goes Global (EVAg) project, which has received
336 funding from the European Union's Horizon 2020 research and innovation programme under grant agreement
337 No 653316.
338 The UNICORN population was recruited thanks to the Funding Action “Ricerche Emergenza coronavirus”,
339 University of Milan, 2020.
340 The authors thank Linda Benincasa for technical support.

341

342

343 **References**

- 344 1. World Health Organization. *WHO Director-General's opening remarks at the media briefing on*
345 *COVID-19 - 11 March 2020*. 2020; Available from: [https://www.who.int/dg/speeches/detail/who-](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
346 [director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020).
347 2. Lu, R., X. Zhao, J. Li, P. Niu, B. Yang, H. Wu, W. Wang, H. Song, B. Huang, N. Zhu, Y. Bi, X. Ma,
348 F. Zhan, L. Wang, T. Hu, H. Zhou, Z. Hu, W. Zhou, L. Zhao, J. Chen, Y. Meng, J. Wang, Y. Lin, J.
349 Yuan, Z. Xie, J. Ma, W.J. Liu, D. Wang, W. Xu, E.C. Holmes, G.F. Gao, G. Wu, W. Chen, W. Shi,

- 350 and W. Tan, *Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for*
351 *virus origins and receptor binding*. Lancet, 2020. **395**(10224): p. 565-574.
- 352 3. Tay, M.Z., C.M. Poh, L. Renia, P.A. MacAry, and L.F.P. Ng, *The trinity of COVID-19: immunity,*
353 *inflammation and intervention*. Nat Rev Immunol, 2020. **20**(6): p. 363-374.
- 354 4. Amanat, F. and F. Krammer, *SARS-CoV-2 Vaccines: Status Report*. Immunity, 2020. **52**(4): p. 583-
355 589.
- 356 5. Chan, J.F., S. Yuan, K.H. Kok, K.K. To, H. Chu, J. Yang, F. Xing, J. Liu, C.C. Yip, R.W. Poon, H.W.
357 Tsoi, S.K. Lo, K.H. Chan, V.K. Poon, W.M. Chan, J.D. Ip, J.P. Cai, V.C. Cheng, H. Chen, C.K. Hui,
358 and K.Y. Yuen, *A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating*
359 *person-to-person transmission: a study of a family cluster*. Lancet, 2020. **395**(10223): p. 514-523.
- 360 6. Zhu, N., D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu, P. Niu, F.
361 Zhan, X. Ma, D. Wang, W. Xu, G. Wu, G.F. Gao, W. Tan, I. China Novel Coronavirus, and T.
362 Research, *A Novel Coronavirus from Patients with Pneumonia in China, 2019*. N Engl J Med, 2020.
363 **382**(8): p. 727-733.
- 364 7. World Health Organization. *MERS SITUATION UPDATE*. 2019 02/16/2021]; Available from:
365 <https://applications.emro.who.int/docs/EMRPUB-CSR-241-2019-EN.pdf?ua=1&ua=1&ua=1>.
- 366 8. Du, L.Y., Y.X. He, Y.S. Zhou, S.W. Liu, B.J. Zheng, and S.B. Jiang, *The spike protein of SARS-CoV*
367 *- a target for vaccine and therapeutic development*. Nature Reviews Microbiology, 2009. **7**(3): p. 226-
368 236.
- 369 9. Huang, C., Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu,
370 J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R.
371 Jiang, Z. Gao, Q. Jin, J. Wang, and B. Cao, *Clinical features of patients infected with 2019 novel*
372 *coronavirus in Wuhan, China*. Lancet, 2020. **395**(10223): p. 497-506.
- 373 10. Jiang, S., C. Hillyer, and L. Du, *Neutralizing Antibodies against SARS-CoV-2 and Other Human*
374 *Coronaviruses: (Trends in Immunology 41, 355-359; 2020)*. Trends Immunol, 2020. **41**(6): p. 545.
- 375 11. Du, L., Y. Yang, Y. Zhou, L. Lu, F. Li, and S. Jiang, *MERS-CoV spike protein: a key target for*
376 *antivirals*. Expert Opin Ther Targets, 2017. **21**(2): p. 131-143.
- 377 12. Young, B.E., S.W.X. Ong, S. Kalimuddin, J.G. Low, S.Y. Tan, J. Loh, O.T. Ng, K. Marimuthu, L.W.
378 Ang, T.M. Mak, S.K. Lau, D.E. Anderson, K.S. Chan, T.Y. Tan, T.Y. Ng, L. Cui, Z. Said, L.
379 Kurupatham, M.I. Chen, M. Chan, S. Vasoo, L.F. Wang, B.H. Tan, R.T.P. Lin, V.J.M. Lee, Y.S. Leo,
380 D.C. Lye, and T. Singapore Novel Coronavirus Outbreak Research, *Epidemiologic Features and*
381 *Clinical Course of Patients Infected With SARS-CoV-2 in Singapore*. JAMA, 2020. **323**(15): p. 1488-
382 1494.
- 383 13. World Health Organization. *WHO Coronavirus Disease (COVID-19) Dashboard*. 2021 12/13/2020];
384 Available from: <https://covid19.who.int/>.
- 385 14. Nations, F.a.A.O.o.t.U. *Impact of COVID-19 on people's livelihoods, their health and our food*
386 *systems*. 2020 02/16/2021]; Available from: <http://www.fao.org/news/story/en/item/1313598/icode/>.
- 387 15. Apolone, G., E. Montomoli, A. Manenti, M. Boeri, F. Sabia, I. Hyseni, L. Mazzini, D. Martinuzzi, L.
388 Cantone, G. Milanese, S. Sestini, P. Suatoni, A. Marchiano, V. Bollati, G. Sozzi, and U. Pastorino,
389 *Unexpected detection of SARS-CoV-2 antibodies in the pre-pandemic period in Italy*. Tumori, 2020: p.
390 300891620974755.
- 391 16. Deslandes, A., V. Berti, Y. Tandjaoui-Lambotte, C. Alloui, E. Carbonnelle, J.R. Zahar, S. Brichtler,
392 and Y. Cohen, *SARS-CoV-2 was already spreading in France in late December 2019*. Int J Antimicrob
393 Agents, 2020. **55**(6): p. 106006.
- 394 17. Amendola, A., S. Bianchi, M. Gori, D. Colzani, M. Canuti, E. Borghi, M.C. Raviglione, G.V. Zuccotti,
395 and E. Tanzi, *Evidence of SARS-CoV-2 RNA in an Oropharyngeal Swab Specimen, Milan, Italy, Early*
396 *December 2019*. Emerg Infect Dis, 2021. **27**(2): p. 648-650.
- 397 18. Gianotti, R., M. Barberis, G. Fellegara, C. Galvan-Casas, and E. Gianotti, *COVID-19-related*
398 *dermatosis in November 2019: could this case be Italy's patient zero?* Br J Dermatol, 2021.
- 399 19. Istituto Superiore di Sanità, *EPIDEMIA COVID-19. Aggiornamento nazionale 2 Aprile 2020*. 2020.
- 400 20. Onder, G., G. Rezza, and S. Brusaferro, *Case-Fatality Rate and Characteristics of Patients Dying in*
401 *Relation to COVID-19 in Italy*. JAMA, 2020. **323**(18): p. 1775-1776.
- 402 21. Istituto Superiore di Sanità, *Caratteristiche dei pazienti deceduti positivi all'infezione da SARS-CoV-*
403 *2 in Italia*. 2020.
- 404 22. Lipsitch, M., D.L. Swerdlow, and L. Finelli, *Defining the Epidemiology of Covid-19 - Studies Needed*.
405 N Engl J Med, 2020. **382**(13): p. 1194-1196.

- 406 23. Milani, G.P., L. Dioni, C. Favero, L. Cantone, C. Macchi, S. Delbue, M. Bonzini, E. Montomoli, V.
407 Bollati, and U. Consortium, *Serological follow-up of SARS-CoV-2 asymptomatic subjects*. Sci Rep,
408 2020. **10**(1): p. 20048.
- 409 24. Manenti, A., M. Maggetti, E. Casa, D. Martinuzzi, A. Torelli, C.M. Trombetta, S. Marchi, and E.
410 Montomoli, *Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live*
411 *virus micro-neutralization assay in human serum samples*. J Med Virol, 2020. **92**(10): p. 2096-2104.
- 412 25. Atyeo, C., S. Fischinger, T. Zohar, M.D. Slein, J. Burke, C. Loos, D.J. McCulloch, K.L. Newman, C.
413 Wolf, J.Y. Yu, K. Shuey, J. Feldman, B.M. Hauser, T. Caradonna, A.G. Schmidt, T.J. Suscovich, C.
414 Linde, Y.F. Cai, D. Barouch, E.T. Ryan, R.C. Charles, D. Lauffenburger, H. Chu, and G. Alter,
415 *Distinct Early Serological Signatures Track with SARS-CoV-2 Survival*. Immunity, 2020. **53**(3): p.
416 524-+.
- 417 26. Wang, Y.Q., L. Zhang, L. Sang, F. Ye, S.C. Ruan, B. Zhong, T. Song, A.N. Alshukairi, R.C. Chen,
418 Z.Y. Zhang, M. Gan, A.R. Zhu, Y.B. Huang, L. Luo, C.K.P. Mok, M.M. Al Gethamy, H.T. Tan, Z.T.
419 Li, X.F. Huang, F. Li, J. Sun, Y.J. Zhang, L.Y. Wen, Y.M. Li, Z. Chen, Z. Zhuang, J.F. Zhuo, C.K.
420 Chen, L.J. Kuang, J.X. Wang, H.B. Lv, Y.L. Jiang, M. Li, Y.M. Lin, Y. Deng, L. Tang, J.L. Liang,
421 J.C. Huang, S. Perlman, N.S. Zhong, J.X. Zhao, J.S.M. Peiris, Y.M. Li, and J.C. Zhao, *Kinetics of viral*
422 *load and antibody response in relation to COVID-19 severity*. Journal of Clinical Investigation, 2020.
423 **130**(10): p. 5235-5244.
- 424 27. Hashem, A.M., A. Algaissi, S.A. Almahboub, M.A. Alfaleh, T.S. Abujamel, S.S. Alamri, K.A.
425 Alluhaybi, H.I. Hobani, R.H. AlHarbi, R.M. Alsulaiman, M.Z. ElAssouli, S. Hala, N.K. Alharbi, R.Y.
426 Alhabbab, A.A. AlSaieedi, W.H. Abdulaal, A. Bukhari, A.A. Al-Somali, F.S. Alofi, A.A. Khogeer,
427 A. Pain, A.A. Alkayyal, N.A.M. Almontashiri, B.M. Ahmad, and X. Li, *Early Humoral Response*
428 *Correlates with Disease Severity and Outcomes in COVID-19 Patients*. Viruses, 2020. **12**(12).
- 429 28. Chen, Y., X. Tong, Y. Li, B. Gu, J. Yan, Y. Liu, H. Shen, R. Huang, and C. Wu, *A comprehensive,*
430 *longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in*
431 *severe and non-severe COVID-19 patients*. PLoS Pathog, 2020. **16**(9): p. e1008796.
- 432 29. Okba, N.M.A., M.A. Muller, W. Li, C. Wang, C.H. GeurtsvanKessel, V.M. Corman, M.M. Lamers,
433 R.S. Sikkema, E. de Bruin, F.D. Chandler, Y. Yazdanpanah, Q. Le Hingrat, D. Descamps, N. Houhou-
434 Fidouh, C. Reusken, B.J. Bosch, C. Drosten, M.P.G. Koopmans, and B.L. Haagmans, *Severe Acute*
435 *Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients*.
436 Emerg Infect Dis, 2020. **26**(7): p. 1478-1488.
- 437 30. Algaissi, A., M.A. Alfaleh, S. Hala, T.S. Abujamel, S.S. Alamri, S.A. Almahboub, K.A. Alluhaybi,
438 H.I. Hobani, R.M. Alsulaiman, R.H. AlHarbi, M.A. ElAssouli, R.Y. Alhabbab, A.A. AlSaieedi, W.H.
439 Abdulaal, A.A. Al-Somali, F.S. Alofi, A.A. Khogeer, A.A. Alkayyal, A.B. Mahmoud, N.A.M.
440 Almontashiri, A. Pain, and A.M. Hashem, *SARS-CoV-2 S1 and N-based serological assays reveal*
441 *rapid seroconversion and induction of specific antibody response in COVID-19 patients*. Sci Rep,
442 2020. **10**(1): p. 16561.
- 443 31. Peeling, R.W., C.J. Wedderburn, P.J. Garcia, D. Boeras, N. Fongwen, J. Nkengasong, A. Sall, A.
444 Tanuri, and D.L. Heymann, *Serology testing in the COVID-19 pandemic response*. Lancet Infect Dis,
445 2020. **20**(9): p. e245-e249.
- 446 32. Reynolds, C.J., L. Swadling, J.M. Gibbons, C. Pade, M.P. Jensen, M.O. Diniz, N.M. Schmidt, D.K.
447 Butler, O.E. Amin, S.N.L. Bailey, S.M. Murray, F.P. Pieper, S. Taylor, J. Jones, M. Jones, W.J. Lee,
448 J. Rosenheim, A. Chandran, G. Joy, C. Di Genova, N. Temperton, J. Lambourne, T. Cutino-Moguel,
449 M. Andiapen, M. Fontana, A. Smit, A. Semper, B. O'Brien, B. Chain, T. Brooks, C. Manisty, T.
450 Treibel, J.C. Moon, C.O. investigators, M. Noursadeghi, C.O.i.c. network, D.M. Altmann, M.K.
451 Maini, A. McKnight, and R.J. Boyton, *Discordant neutralizing antibody and T cell responses in*
452 *asymptomatic and mild SARS-CoV-2 infection*. Sci Immunol, 2020. **5**(54).
- 453 33. Roltgen, K., A.E. Powell, O.F. Wirz, B.A. Stevens, C.A. Hogan, J. Najeeb, M. Hunter, H. Wang, M.K.
454 Sahoo, C. Huang, F. Yamamoto, M. Manohar, J. Manalac, A.R. Otrelo-Cardoso, T.D. Pham, A.
455 Rustagi, A.J. Rogers, N.H. Shah, C.A. Blish, J.R. Cochran, T.S. Jardetzky, J.L. Zehnder, T.T. Wang,
456 B. Narasimhan, S. Gombar, R. Tibshirani, K.C. Nadeau, P.S. Kim, B.A. Pinsky, and S.D. Boyd,
457 *Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with*
458 *disease severity and outcome*. Sci Immunol, 2020. **5**(54).
- 459 34. Yao, T., Y. Gao, Q. Cui, B. Peng, Y. Chen, J. Li, C. Huang, C. He, J. Pu, J. Wei, Y. Zhan, J. Yan, J.
460 Tian, Z. Zhang, and Z. Liu, *Clinical characteristics of a group of deaths with COVID-19 pneumonia*
461 *in Wuhan, China: a retrospective case series*. BMC Infect Dis, 2020. **20**(1): p. 695.
- 462 35. Di Domenico, S.L., D. Coen, M. Bergamaschi, V. Albertini, L. Ghezzi, M.M. Cazzaniga, V. Tombini,
463 R. Colombo, N. Capsoni, T. Coen, K.B. Cazzola, M. Di Fiore, L. Angaroni, and M.A. Strozzi, *Clinical*

464 *characteristics and respiratory support of 310 COVID-19 patients, diagnosed at the emergency room:*
465 *a single-center retrospective study.* Internal and Emergency Medicine, 2020.
466





Figure 1. S1 IgM titres in COVID-19 patients (recovered and deceased) and asymptomatic subjects. Black dashed line indicates positivity threshold at 12 U/ml.

Legends for figures:

COVID-19 Patients



Asymptomatic subjects







Figure 2. S1 IgA titres in COVID-19 patients (recovered and deceased) and asymptomatic subjects. Black dashed line indicates positivity threshold at 12 U/ml.

Legends for figures:


COVID-19 Patients

Sex ■ M ▲ F



Asymptomatic subjects

Sex ■ F ▲ M








Figure 3. S1 IgG titres in COVID-19 patients (recovered and deceased) and asymptomatic subjects. Black dashed line indicates positivity threshold at 12 U/ml.

Legends for figures:

COVID-19 Patients



Asymptomatic subjects







Figure 4. NP IgG titres in COVID-19 patients (recovered and deceased) and asymptomatic subjects. Black dashed line indicates positivity threshold at 12 U/ml.

Legends for figures:

COVID-19 Patients



Asymptomatic subjects







Figure 5. Neutralizing antibody (NAb) titres in COVID-19 patients (recovered and deceased) and asymptomatic subjects.

Legends for figures:


COVID-19 Patients

Sex ■ M ▲ F



Asymptomatic subjects

Sex ■ F ▲ M






Figure 6. Correlations between antibody for COVID-19 patients. Titres are shown as log-2 transformed.